206 related articles for article (PubMed ID: 264689)
1. Inhibition of erythrocyte sickling in vitro by DL-glyceraldehyde.
Nigen AM; Manning JM
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):367-71. PubMed ID: 264689
[TBL] [Abstract][Full Text] [Related]
2. Modification of sickle hemoglobin by acetaldehyde and its effect on oxygenation, gelation and sickling.
Abraham EC; Stallings M; Abraham A; Garbutt GJ
Biochim Biophys Acta; 1982 Jul; 705(1):76-81. PubMed ID: 7115734
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of deoxyhemoglobin S polymerization by glyceraldehyde.
Acharya AS; Sussman LG; Jones WM; Manning JM
Anal Biochem; 1984 Jan; 136(1):101-9. PubMed ID: 6711801
[TBL] [Abstract][Full Text] [Related]
4. Effects of glyceraldehyde on the structural and functional properties of sickle erythrocytes.
Nigen AM; Manning JM
J Clin Invest; 1978 Jan; 61(1):11-9. PubMed ID: 618907
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of erythrocyte sickling in vitro by pyridoxal.
Kark JA; Kale MP; Tarassoff PG; Woods M; Lessin LS
J Clin Invest; 1978 Oct; 62(4):888-91. PubMed ID: 701485
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
Manning JM; Acharya AS
Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
[TBL] [Abstract][Full Text] [Related]
7. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Devlin MT; Schwartz E
Biochim Biophys Acta; 1981 May; 668(3):397-405. PubMed ID: 7236716
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of erythrocyte sickling by cystamine, a thiol reagent.
Hassan W; Beuzard Y; Rosa J
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3288-92. PubMed ID: 135260
[TBL] [Abstract][Full Text] [Related]
9. Sickle cells modified by an osmotic pulse in the presence of inositol hexaphosphate have decreased intracellular hemoglobin concentration and decreased in vitro sickling without prolonged in vivo survival.
Franco R; Barker-Gear R; Silberstein E; Mayfield G; Weiner M; Palascak J; Green R
Adv Exp Med Biol; 1992; 326():325-31. PubMed ID: 1295319
[TBL] [Abstract][Full Text] [Related]
10. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro.
Cerami A; Manning JM
Proc Natl Acad Sci U S A; 1971 Jun; 68(6):1180-3. PubMed ID: 5288366
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl adipimidate: a new antisickling agent.
Lubin BH; Pena V; Mentzer WC; Bymun E; Bradley TB; Packer L
Proc Natl Acad Sci U S A; 1975 Jan; 72(1):43-6. PubMed ID: 1054514
[TBL] [Abstract][Full Text] [Related]
12. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences.
Fabry ME; Kaul DK; Raventos-Suarez C; Chang H; Nagel RL
J Clin Invest; 1982 Dec; 70(6):1315-9. PubMed ID: 7174796
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2-hemoglobin AA and SS erythrocyte interaction (prostaglandin-erythrocyte interaction).
Sobota JT; Gruber CA; Gilbertson TJ; Wilson J
Am J Hematol; 1977; 2(2):133-43. PubMed ID: 18932
[TBL] [Abstract][Full Text] [Related]
14. Effects of carbon dioxide and pH variations in vitro on blood respiratory functions, red blood cell volume, transmembrane pH gradients, and sickling in sickle cell anemia.
Ueda Y; Bookchin RM
J Lab Clin Med; 1984 Aug; 104(2):146-59. PubMed ID: 6431043
[TBL] [Abstract][Full Text] [Related]
15. Effects of methyl acetyl phosphate, a covalent antisickling agent, on the density profiles of sickle erythrocytes.
Ueno H; Yatco E; Benjamin LJ; Manning JM
J Lab Clin Med; 1992 Jul; 120(1):152-8. PubMed ID: 1613320
[TBL] [Abstract][Full Text] [Related]
16. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
[TBL] [Abstract][Full Text] [Related]
17. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
18. The delay time in sickle cell disease after 40 years: A paradigm assessed.
Ferrone FA
Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011
[TBL] [Abstract][Full Text] [Related]
19. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
[TBL] [Abstract][Full Text] [Related]
20. The effect of aspirin on sickling and oxygen affinity of erythrocytes.
De Furia FG; Cerami A; Bunn HF; Lu YS; Peterson CM
Proc Natl Acad Sci U S A; 1973 Dec; 70(12):3707-10. PubMed ID: 4521198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
